Last reviewed · How we verify
General Corticotherapy
General corticotherapy suppresses immune and inflammatory responses through glucocorticoid receptor activation, reducing inflammation and modulating immune cell function.
General corticotherapy suppresses immune and inflammatory responses through glucocorticoid receptor activation, reducing inflammation and modulating immune cell function. Used for Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial not specified).
At a glance
| Generic name | General Corticotherapy |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids bind to glucocorticoid receptors in the cytoplasm, translocate to the nucleus, and modulate gene expression to decrease production of pro-inflammatory cytokines, reduce immune cell proliferation and migration, and stabilize cell membranes. This broad immunosuppressive and anti-inflammatory effect makes corticosteroids useful across multiple therapeutic areas, though their non-selective mechanism also contributes to significant adverse effects with prolonged use.
Approved indications
- Inflammatory and autoimmune conditions (specific indication under investigation in phase 3 trial not specified)
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Immunosuppression / increased infection risk
- Cushingoid features
- Mood disturbances
Key clinical trials
- Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus (PHASE3)
- Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma (NA)
- Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- General Corticotherapy CI brief — competitive landscape report
- General Corticotherapy updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI